Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Mark H.H. Kramer"'
Autor:
Lennart Tonneijck, Mark M. Smits, Mark H.H. Kramer, D. Margriet Ouwens, Marcel H.A. Muskiet, Daniël H. van Raalte, Jordan Kraaijenhof
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ae87a2589ffb6b86e18c36313f4a1c1
https://doi.org/10.1111/dom.14107/v2/response1
https://doi.org/10.1111/dom.14107/v2/response1
Autor:
Daniël H. van Raalte, Trynke Hoekstra, Mark M. Smits, Michaela Diamant, Piet M. ter Wee, Jaap A. Joles, Marcel H.A. Muskiet, Lennart Tonneijck, A.H. Jan Danser, Mark H.H. Kramer
Publikováno v:
Diabetes Care, 42(3). American Diabetes Association Inc.
Tonneijck, L, Smits, M M, Muskiet, M H A, Hoekstra, T, Kramer, M H H, Danser, A H J, Ter Wee, P M, Diamant, M, Joles, J A & van Raalte, D H 2019, ' Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes : A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050 ', Diabetes Care, vol. 42, no. 3 . https://doi.org/10.2337/dc19-er03
Tonneijck, L, Smits, M M, Muskiet, M H A, Hoekstra, T, Kramer, M H H, Danser, A H J, Ter Wee, P M, Diamant, M, Joles, J A & van Raalte, D H 2019, ' Erratum. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes : a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2016;39:2042-2050 ', Diabetes Care, vol. 42, no. 3 . https://doi.org/10.2337/dc19-er03
Diabetes Care
Tonneijck, L, Smits, M M, Muskiet, M H A, Hoekstra, T, Kramer, M H H, Danser, A H J, Ter Wee, P M, Diamant, M, Joles, J A & van Raalte, D H 2019, ' Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes : A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042-2050 ', Diabetes Care, vol. 42, no. 3 . https://doi.org/10.2337/dc19-er03
Tonneijck, L, Smits, M M, Muskiet, M H A, Hoekstra, T, Kramer, M H H, Danser, A H J, Ter Wee, P M, Diamant, M, Joles, J A & van Raalte, D H 2019, ' Erratum. Renal effects of DPP-4 inhibitor sitagliptin or GLP-1 receptor agonist liraglutide in overweight patients with type 2 diabetes : a 12-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2016;39:2042-2050 ', Diabetes Care, vol. 42, no. 3 . https://doi.org/10.2337/dc19-er03
Diabetes Care
To investigate effects of dipeptidyl peptidase-4 inhibitor (DPP-4I) sitagliptin or glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide treatment on renal hemodynamics, tubular functions, and markers of renal damage in overweight patients wit
Autor:
Edmée J M Schrijver, Anne M Lagaay, Mark H.H. Kramer, Pierre M. Bet, Sabine H.A. Diepeveen, Leo Boelaarts, Prabath W. B. Nanayakkara, Peter M. van de Ven, Oscar J. de Vries, Frank W. Bloemers, Astrid M van Strien, Rob J. van Marum, Sander Anten, Ad M Kamper
Publikováno v:
Schrijver, E J M, De Vries, O J, Van De Ven, P M, Bet, P M, Kamper, A M, Diepeveen, S H A, Van Marum, R J, Van Strien, A M, Anten, S, Lagaay, A M, Boelaarts, L, Bloemers, F W, Kramer, M H H & Nanayakkara, P W B 2018, ' Haloperidol versus placebo for delirium prevention in acutely hospitalised older at risk patients : A multi-centre double-blind randomised controlled clinical trial ', Age and Ageing, vol. 47, no. 1, pp. 48-55 . https://doi.org/10.1093/ageing/afx124
Age and Ageing, 47(1), 48-55. Oxford University Press
Age and Ageing, 47(1), 48-55. Oxford University Press
Background: because the few randomised placebo-controlled trials investigating the potential role for prophylactic haloperidol in delirium prevention have focused on specific surgical populations, we investigated its efficacy and safety in acutely ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeb35962f9c9321b008d6db22570a9eb
https://research.vumc.nl/en/publications/fa60d21d-5e9b-4f4a-9792-9e606da4eeff
https://research.vumc.nl/en/publications/fa60d21d-5e9b-4f4a-9792-9e606da4eeff
Autor:
Mark H.H. Kramer, Petra J. W. Pouwels, Djuna L. Cahen, Indra C. Pieters-van den Bos, Daniël H. van Raalte, Lennart Tonneijck, Mark M. Smits, Michaela Diamant, Karuna E W Vendrik, Marcel H.A. Muskiet
Publikováno v:
Vendrik, K E W, Tonneijck, L, Muskiet, M H A, Kramer, M H H, Pouwels, P J W, Pieters-Van Den Bos, I C, Diamant, M, Cahen, D L, Van Raalte, D H & Smits, M M 2017, ' Pancreatic Steatosis Is Not Associated with Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients ', Pancreas, vol. 46, no. 9, pp. e75-e76 . https://doi.org/10.1097/MPA.0000000000000893
ResearcherID
Pancreas, 46(9), e75-e76. Lippincott Williams and Wilkins
Pancreas, 46(9), E75-E76. Lippincott Williams & Wilkins
ResearcherID
Pancreas, 46(9), e75-e76. Lippincott Williams and Wilkins
Pancreas, 46(9), E75-E76. Lippincott Williams & Wilkins
Autor:
Paul Lips, Elisabeth M.W. Eekhoff, Mark H.H. Kramer, R. Meijnen, D.L. Knol, N.M. van Schoor, Mirjam M. Oosterwerff, M.N.M. van Poppel
Publikováno v:
Oosterwerff, M M, Meijnen, R, van Schoor, N M, Knol, D L, Kramer, M H H, van Poppel, M N M, Lips, P T A M & Eekhoff, E M W 2014, ' Effect of vitamin D supplementation on physical performance and activity in non-western immigrants ', Endocrine Connections, vol. 3, no. 4, pp. 224-232 . https://doi.org/10.1530/EC-14-0096
Endocrine Connections
Endocrine Connections, 3(4), 224-232. BioScientifica
Endocrine Connections, 3(4), 224-232. BioScientifica Ltd.
Endocrine Connections
Endocrine Connections, 3(4), 224-232. BioScientifica
Endocrine Connections, 3(4), 224-232. BioScientifica Ltd.
Vitamin D deficiency is highly prevalent among non-western immigrants in The Netherlands and associated with poor physical performance. The aim of this study was to assess the effect of vitamin D supplementation on physical performance, exercise capa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cf720385618f6271997bb840451ddc2
https://research.vumc.nl/en/publications/11aa77cb-77ac-43f5-bdd1-d8d02b0131f4
https://research.vumc.nl/en/publications/11aa77cb-77ac-43f5-bdd1-d8d02b0131f4
Autor:
Cornelis Jakobs, Ron A. Wevers, Prabath W. B. Nanayakkara, Mark H.H. Kramer, Martina Meijboom
Publikováno v:
The Lancet (London), 376, 1710-1710
Nanayakkara, P W B, Meijboom, M, Kramer, M H H, Wevers, R A & Jakobs, C 2010, ' What have we here? A man or a fish? ', Lancet, vol. 376, no. 9753, pp. 1710-1710 . https://doi.org/10.1016/S0140-6736(10)61151-8
Lancet, 376(9753), 1710-1710. Elsevier Limited
The Lancet (London), 376, 9753, pp. 1710-1710
Nanayakkara, P W B, Meijboom, M, Kramer, M H H, Wevers, R A & Jakobs, C 2010, ' What have we here? A man or a fish? ', Lancet, vol. 376, no. 9753, pp. 1710-1710 . https://doi.org/10.1016/S0140-6736(10)61151-8
Lancet, 376(9753), 1710-1710. Elsevier Limited
The Lancet (London), 376, 9753, pp. 1710-1710
In January, 2006, a 45-year-old man presented to our department; he complained of a strong objectionable body odour, resembling the aroma of fi sh, which had a profound infl uence on his life. He decided to seek help, because of marital problems rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ce03d6777db827b4149faba5a0446d
http://hdl.handle.net/2066/87432
http://hdl.handle.net/2066/87432
Autor:
Mark H.H. Kramer, Hiddo J.L. Heerspink, Lennart Tonneijck, Daniël H. van Raalte, Marcel H.A. Muskiet, Mark M. Smits
Publikováno v:
ResearcherID
Lancet diabetes & endocrinology, 3(5), 367-381. Elsevier BV
Muskiet, M H A, Tonneijck, L, Smits, M M, Kramer, M H H, Heerspink, H J L & van Raalte, D H 2015, ' Pleiotropic effects of type 2 diabetes management strategies on renal risk factors ', Lancet diabetes & endocrinology, vol. 3, no. 5, pp. 367-381 . https://doi.org/10.1016/S2213-8587(15)00030-3
Lancet diabetes & endocrinology, 3(5), 367-381. Elsevier BV
Muskiet, M H A, Tonneijck, L, Smits, M M, Kramer, M H H, Heerspink, H J L & van Raalte, D H 2015, ' Pleiotropic effects of type 2 diabetes management strategies on renal risk factors ', Lancet diabetes & endocrinology, vol. 3, no. 5, pp. 367-381 . https://doi.org/10.1016/S2213-8587(15)00030-3
In parallel with the type 2 diabetes pandemic, diabetic kidney disease has become the leading cause of end-stage renal disease worldwide, and is associated with high cardiovascular morbidity and mortality. As established in landmark randomised trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef94f8baaec43a95ece98c31d515853
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000353413700020&KeyUID=WOS:000353413700020
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000353413700020&KeyUID=WOS:000353413700020